A fully caninised anti-NGF monoclonal antibody for pain relief in dogs

BMC Veterinary Research

Volumn 9, Issue , 2013, Pages

  Gearing, David P ^a,b   Virtue, Elena R ^a   Gearing, Robert P ^a   Drew, Alexander C ^b  

^a Nexvet Biopharma Pty Ltd   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Analgesia; Chronic pain; Companion animals; Monoclonal antibody; Nerve growth factor; Pharmacokinetics; Veterinary bio therapeutic

Indexed keywords

ANIMALIA; CANIS FAMILIARIS; RATTUS; RODENTIA;

MONOCLONAL ANTIBODY; NERVE GROWTH FACTOR; RECOMBINANT PROTEIN;

AMINO ACID SEQUENCE; ANALGESIA; ANIMAL; ANIMAL DISEASE; ARTICLE; CHRONIC PAIN; DOG; DOG DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETICS; HUMAN; IMMUNOLOGY; INFLAMMATION; MALE; METHODOLOGY; MOUSE; PAIN; SEQUENCE ALIGNMENT;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; CHRONIC PAIN; DOG DISEASES; DOGS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFLAMMATION; MALE; MICE; NERVE GROWTH FACTOR; PAIN; PAIN MANAGEMENT; RECOMBINANT PROTEINS; SEQUENCE ALIGNMENT;

EID: 84887090038     PISSN: None     EISSN: 17466148     Source Type: Journal    
DOI: 10.1186/1746-6148-9-226     Document Type: Article

References (33)

1. Wernham BG, Trumpatori B, Hash J, Lipsett J, Davidson G, Wackerow P, Thomson A, Lascelles BD. Dose reduction of meloxicam in dogs with osteoarthritis-associated pain and impaired mobility. J Vet Intern Med/American College of Veterinary Internal Medicine 2011, 25(6):1298-1305.
2. Papich MG. An update on nonsteroidal anti-inflammatory drugs (NSAIDs) in small animals. Vet Clin N Am Small Anim Pract 2008, 38(6):1243-1266. vi.
3. Levi-Montalcini R. The nerve growth factor 35 years later. Science 1987, 237(4819):1154-1162. 10.1126/science.3306916, 3306916.
4. Levi-Montalcini R, Skaper SD, Dal Toso R, Petrelli L, Leon A. Nerve growth factor: from neurotrophin to neurokine. Trends Neurosci 1996, 19(11):514-520. 10.1016/S0166-2236(96)10058-8, 8931279.
5. Hefti FF, Rosenthal A, Walicke PA, Wyatt S, Vergara G, Shelton DL, Davies AM. Novel class of pain drugs based on antagonism of NGF. Trends Pharmacol Sci 2006, 27(2):85-91.
6. Mantyh PW, Koltzenburg M, Mendell LM, Tive L, Shelton DL. Antagonism of nerve growth factor-TrkA signaling and the relief of pain. Anesthesiology 2011, 115(1):189-204. 10.1097/ALN.0b013e31821b1ac5, 3121917, 21602663.
7. Cattaneo A. Tanezumab, a recombinant humanized mAb against nerve growth factor for the treatment of acute and chronic pain. Curr Opin Mol Ther 2010, 12(1):94-106.
8. Ghilardi JR, Freeman KT, Jimenez-Andrade JM, Coughlin KA, Kaczmarska MJ, Castaneda-Corral G, Bloom AP, Kuskowski MA, Mantyh PW. Neuroplasticity of sensory and sympathetic nerve fibers in a mouse model of a painful arthritic joint. Arthritis Rheum 2012, 64(7):2223-2232. 10.1002/art.34385, 3386465, 22246649.
9. Brown MT, Murphy FT, Radin DM, Davignon I, Smith MD, West CR. Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial. Arthritis Rheum 2013, 65(7):1795-1803. 10.1002/art.37950, 23553790.
10. Katz N, Borenstein DG, Birbara C, Bramson C, Nemeth MA, Smith MD, Brown MT. Efficacy and safety of tanezumab in the treatment of chronic low back pain. Pain 2011, 152(10):2248-2258. 10.1016/j.pain.2011.05.003, 21696889.
11. Lane NE, Schnitzer TJ, Birbara CA, Mokhtarani M, Shelton DL, Smith MD, Brown MT. Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med 2010, 363(16):1521-1531. 10.1056/NEJMoa0901510, 20942668.
12. Nagashima H, Suzuki M, Araki S, Yamabe T, Muto C, Tanezumab I. Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, double-blind, dose-escalation, placebo-controlled study. Osteoarthritis Cartilage/OARS, Osteoarthritis Research Society 2011, 19(12):1405-1412.
13. Zorbas M, Hurst S, Shelton D, Evans M, Finco D, Butt M. A multiple-dose toxicity study of tanezumab in cynomolgus monkeys. Regul Toxicol Pharmacol 2011, 59(2):334-342. 10.1016/j.yrtph.2010.11.005, 21130822.
14. Garber K. Fate of novel painkiller mAbs hangs in balance. Nat Biotechnol 2011, 29(3):173-174. 10.1038/nbt0311-173, 21389990.
15. Food and Drug Administration (USA) Summary minutes of the arthritis advisory committee meeting March 12, 2012 2012, Center for Drug Evaluation and Research, http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM307879.pdf. Accessed November 2013, Food and Drug Administration (USA).
16. D'Intino G, Vaccari F, Sivilia S, Scagliarini A, Gandini G, Giardino L, Calza L. A molecular study of hippocampus in dogs with convulsion during canine distemper virus encephalitis. Brain Res 2006, 1098(1):186-195. 10.1016/j.brainres.2006.04.051, 16765333.
17. Fan TM, Barger AM, Sprandel IT, Fredrickson RL. Investigating TrkA expression in canine appendicular osteosarcoma. J Vet Intern Med/American College of Veterinary Internal Medicine 2008, 22(5):1181-1188.
18. Ryan VH, German AJ, Wood IS, Hunter L, Morris P, Trayhurn P. NGF gene expression and secretion by canine adipocytes in primary culture: upregulation by the inflammatory mediators LPS and TNFalpha. Horm Metab Res = Hormon- und Stoffwechselforschung = Hormones et metabolisme 2008, 40(12):861-868.
19. Woo HM, Bentley E, Campbell SF, Marfurt CF, Murphy CJ. Nerve growth factor and corneal wound healing in dogs. Exp Eye Res 2005, 80(5):633-642. 10.1016/j.exer.2004.11.013, 15862170.
20. Isola M, Ferrari V, Miolo A, Stabile F, Bernardini D, Carnier P, Busetto R. Nerve growth factor concentrations in the synovial fluid from healthy dogs and dogs with secondary osteoarthritis. Vet Comp Orthop Traumatol 2011, 24(4):279-284. 10.3415/VCOT-10-04-0051, 21674121.
21. Tang L, Sampson C, Dreitz MJ, McCall C. Cloning and characterization of cDNAs encoding four different canine immunoglobulin gamma chains. Vet Immunol Immunopathol 2001, 80(3-4):259-270.
22. Albanesi M, Daeron M. The interactions of therapeutic antibodies with Fc receptors. Immunol Lett 2012, 143(1):20-27. 10.1016/j.imlet.2012.02.005, 22553779.
23. Hinton PR, Johlfs MG, Xiong JM, Hanestad K, Ong KC, Bullock C, Keller S, Tang MT, Tso JY, Vasquez M, et al. Engineered human IgG antibodies with longer serum half-lives in primates. J Biol Chem 2004, 279(8):6213-6216.
24. Mould DR, Sweeney KR. The pharmacokinetics and pharmacodynamics of monoclonal antibodies-mechanistic modeling applied to drug development. Curr Opin Drug Discov Dev 2007, 10(1):84-96.
25. Ruberti F, Bradbury A, Cattaneo A. Cloning and expression of an anti-nerve growth factor (NGF) antibody for studies using the neuroantibody approach. Cell Mol Neurobiol 1993, 13(5):559-568. 10.1007/BF00711464, 8111827.
26. Lewis MJ, Wagner B, Woof JM. The different effector function capabilities of the seven equine IgG subclasses have implications for vaccine strategies. Cell Mol Immunol 2008, 45(3):818-827.
27. Paetz A, Sack M, Thepen T, Tur MK, Bruell D, Finnern R, Fischer R, Barth S. Recombinant soluble human Fcgamma receptor I with picomolar affinity for immunoglobulin G. Biochem Biophys Res Commun 2005, 338(4):1811-1817. 10.1016/j.bbrc.2005.10.162, 16289041.
28. Giraudel JM, Diquelou A, Laroute V, Lees P, Toutain PL. Pharmacokinetic/pharmacodynamic modelling of NSAIDs in a model of reversible inflammation in the cat. Br J Pharmacol 2005, 146(5):642-653. 10.1038/sj.bjp.0706372, 1751204, 16113689.
29. Jeunesse EC, Bargues IA, Toutain CE, Lacroix MZ, Letellier IM, Giraudel JM, Toutain PL. Paw inflammation model in dogs for preclinical pharmacokinetic/pharmacodynamic investigations of nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 2011, 338(2):548-558. 10.1124/jpet.110.178350, 21525206.
30. Kitamura T, Tojo A, Kuwaki T, Chiba S, Miyazono K, Urabe A, Takaku F. Identification and analysis of human erythropoietin receptors on a factor-dependent cell line, TF-1. Blood 1989, 73(2):375-380.
31. Queen C, Schneider WP, Selick HE, Payne PW, Landolfi NF, Duncan JF, Avdalovic NM, Levitt M, Junghans RP, Waldmann TA. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci USA 1989, 86(24):10029-10033. 10.1073/pnas.86.24.10029, 298637, 2513570.
32. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988, 332(6162):323-327. 10.1038/332323a0, 3127726.
33. Covaceuszach S, Cassetta A, Konarev PV, Gonfloni S, Rudolph R, Svergun DI, Lamba D, Cattaneo A. Dissecting NGF interactions with TrkA and p75 receptors by structural and functional studies of an anti-NGF neutralizing antibody. J Mol Biol 2008, 381(4):881-896. 10.1016/j.jmb.2008.06.008, 18635195.